Markus Schwaiger, MD, receives SNMMI Georg Charles de Hevesy Nuclear Pioneer Award

June 21, 2022 — Markus Schwaiger, MD, a scientist known for his contributions to cardiac PET imaging, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award. Schwaiger was presented the award by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) at its 2022 Annual Meeting.

Schwaiger is recognized for his significant work in multimodal imaging to visualize and quantify biologic processes. His played a key role in the advancement of nuclear cardiology, focusing on molecular mechanisms to develop novel quantitative methods and radiotracers. His translational approach included both preclinical and clinical trials, resulting in the creation of novel diagnostic and image-guided therapeutic paradigms. Schwaiger’s research interests also included oncologic PET, as well as the diagnosis and treatment of thyroid endocrine and neuroendocrine diseases.

“Dr. Schwaiger has proven himself a scientific, clinical educational and administrative leader throughout his entire career,” said SNMMI President Richard L. Wahl, MD, FACNM. “From his work in establishing PET as the standard for myocardial viability to his pioneering role in PET/MRI imaging, his training of new generations of nuclear medicine leaders, and his establishment of centers of excellence at the Technical University of Munich, his dedication to the field has profoundly changed the way we practice nuclear medicine and molecular imaging.”

Schwaiger completed his medical studies at the University of Freiburg and Freie Universität Berlin in Germany. He completed a post-doctoral fellowship at the University of Cincinnati in Ohio and returned to Germany as a resident at the German Heart Center in Munich. From there, his career took him to the University of California, Los Angeles, where, as a fellow and assistant professor, he utilized PET to contribute novel insights to the field of cardiology. In 1986, Schwaiger moved to the University of Michigan and led the nuclear cardiology & cardiac PET program in Ann Arbor. Schwaiger returned to Germany in 1993, serving as the director of the Department of Nuclear Medicine at the Klinikum rechts der Isar of the Technical University of Munich. In 2016, he became the medical director and CEO for the Klinikum rechts der Isar of the Technical University of Munich, and he retired in 2021.

“I am honored to receive SNMMI’s Georg Charles de Hevesy Nuclear Medicine Pioneer Award,” said Schwaiger. “At every stage throughout my career I have had the pleasure of working with  very talented colleagues who inspired and supported me. Together we have advanced the field of nuclear medicine and molecular imaging. Now, I am excited to observe and to applaud what the next generation of researchers in nuclear medicine will discover.”

Each year, SNMMI presents the Georg Charles de Hevesy Nuclear Medicine Pioneer Award to an individual for outstanding contributions to the field of nuclear medicine. De Hevesy received the 1943 Nobel Prize in chemistry for his work in determining the absorption, distribution, metabolism and elimination of radioactive compounds in the human body. His work led to the foundation of nuclear medicine as a tool for diagnosis and therapy, and he is considered the father of nuclear medicine. SNMMI has given the de Hevesy Award every year since 1960 to honor groundbreaking work in the field of nuclear medicine.

The list of previous recipients of this award includes numerous Nobel laureates—such as Ernest Lawrence, who built the world’s first cyclotron for the production of radionuclides, and Glenn Seaborg, who discovered more than half a dozen new elements. 

For more information: www.snmmi.org

Find more SNMMI22 coverage here


Related Content

News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
News | Prostate Cancer

July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 30, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 25, 2024 — NorthStar Medical Radioisotopes, LLC and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc ...

Time July 25, 2024
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | Radiology Imaging

July 23, 2024 — EMVision, an Australian medical device company focused on the development and commercialization of ...

Time July 23, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Computed Tomography (CT)

July 15, 2024 — NeuroLogica Corp, a subsidiary of Samsung Electronics Co. Ltd., announced its latest configuration of ...

Time July 15, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
Feature | SCCT | by Christine Book

June 27, 2024 — The countdown has begun for the Society of Cardiovascular Computed Tomography (SCCT) 19th Annual ...

Time June 27, 2024
arrow
Subscribe Now